Previous Close | 59.66 |
Open | 59.84 |
Bid | 42.42 x 1400 |
Ask | 99.93 x 800 |
Day's Range | 58.65 - 63.28 |
52 Week Range | 45.20 - 104.38 |
Volume | |
Avg. Volume | 565,835 |
Market Cap | 4.349B |
Beta (5Y Monthly) | 1.67 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Taking the occasional loss comes part and parcel with investing on the stock market. And there's no doubt that...
Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.
Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.